Versant Capital Management
CTKB icon

Versant Capital Management’s Cytek Biosciences CTKB Stock Holding History

Versant Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.82K Sell
473
-42
-8% -$199 ﹤0.01% 2560
2026
Q2 		$2.28K Sell
515
-2,220
-81% -$9.48K ﹤0.01% 2547
2026
Q1 		$12K Buy
2,735
+2,300
+529% +$10.9K ﹤0.01% 2060
2025
Q4 		$2.2K Hold
435
– – ﹤0.01% 2440
2025
Q3 		$1.51K Buy
435
+284
+188% +$1.07K ﹤0.01% 2455
2025
Q2 		$513 Sell
151
-788
-84% -$2.63K ﹤0.01% 2548
2025
Q1 		$3.76K Sell
939
-89
-9% -$461 ﹤0.01% 2126
2024
Q4 		$6.67K Hold
1,028
– – ﹤0.01% 1613
2024
Q3 		$5.7K Buy
+1,028
New +$5.83K ﹤0.01% 1259
2023
Q4 		– Sell
-286
Closed -$1.58K – 1945
2023
Q3 		$1.58K Buy
+286
New +$2.29K ﹤0.01% 1385

Other funds holding CTKB

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return

Versant Capital Management's CTKB Position: Q3 2026 in Review

Versant Capital Management reduced its Cytek Biosciences (CTKB) stake by 8.2% in Q3 2026, selling an estimated $199 and leaving 473 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #2560.

Versant Capital Management first reported a position in CTKB in Q3 2023 and has held it in 10 quarters since. The position peaked at $12K in Q1 2026. 107 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Versant Capital Management held 473 shares of Cytek Biosciences worth $2.82K as of Q3 2026.
  • Versant Capital Management sold 42 Cytek Biosciences shares in Q3 2026, an estimated $199.
  • Cytek Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2560 holding.
  • Versant Capital Management first reported a position in Cytek Biosciences in Q3 2023 and has held it in 10 quarters since.
  • Versant Capital Management's Cytek Biosciences position peaked at $12K in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.